Wiseman Sam M, Griffith Obi L, Deen Shaun, Rajput Ashish, Masoudi Hamid, Gilks Blake, Goldstein Lynn, Gown Allen, Jones Steven J M
Department of Surgery, St Paul's Hospital, University of British Columbia, C303-1081 Burrard St, Vancouver, BC, Canada V6Z-1Y6.
Arch Surg. 2007 Aug;142(8):717-27; discussion 727-9. doi: 10.1001/archsurg.142.8.717.
A change in tumor expression profile will be observed during the transformation of differentiated into anaplastic thyroid carcinoma.
Cohort study.
Population-based sample (British Columbia).
Sequential archival cases of anaplastic thyroid cancer with an adjacent associated differentiated thyroid cancer focus, and with available paraffin blocks, that had been diagnosed and treated in British Columbia during a 20-year period (12 cases; January 1, 1984, through December 31, 2004) were identified through the provincial tumor registry for tissue microarray construction.
Significant associations between marker staining and tumor pathologic diagnosis (differentiated vs anaplastic) were determined with contingency table and marginal homogeneity tests. A classifier algorithm was also used to identify useful and important molecular classifiers.
Overall, there were 3 up-regulated and 5 down-regulated markers when comparing the anaplastic carcinoma with associated differentiated thyroid cancers. Contingency table statistics identified 5 markers (thyroglobulin, Bcl-2, MIB-1, E-cadherin, and p53) to be significantly differentially expressed by the anaplastic and differentiated tumor foci. These 5 markers and 3 others (beta-catenin, topoisomerase II-alpha, and vascular endothelial growth factor) were significant when evaluated using the marginal homogeneity test. Clustering and classification analysis based on these same 8 markers readily separated differentiated and anaplastic thyroid tumors with a high degree of accuracy.
The markers we observed to change during thyroid tumor progression may not only show promise as molecular diagnostic or prognostic tools but also warrant further study as potential targets for treatment of disease.
在分化型甲状腺癌向间变性甲状腺癌转变过程中,将观察到肿瘤表达谱的变化。
队列研究。
基于人群的样本(不列颠哥伦比亚省)。
通过省级肿瘤登记处识别出在20年期间(1984年1月1日至2004年12月31日)在不列颠哥伦比亚省诊断和治疗的、具有相邻相关分化型甲状腺癌灶且有石蜡块可用的间变性甲状腺癌连续存档病例(12例),用于构建组织微阵列。
通过列联表和边际齐性检验确定标志物染色与肿瘤病理诊断(分化型与间变性)之间的显著关联。还使用分类算法来识别有用且重要的分子分类器。
总体而言,将间变性癌与相关分化型甲状腺癌进行比较时,有3个标志物上调,5个标志物下调。列联表统计确定5个标志物(甲状腺球蛋白、Bcl-2、MIB-1、E-钙黏蛋白和p53)在间变性和分化型肿瘤灶中显著差异表达。使用边际齐性检验评估时,这5个标志物以及其他3个标志物(β-连环蛋白、拓扑异构酶II-α和血管内皮生长因子)具有显著性。基于这相同的8个标志物进行聚类和分类分析,能够以高度准确性轻松区分分化型和间变性甲状腺肿瘤。
我们观察到在甲状腺肿瘤进展过程中发生变化的标志物,不仅有望作为分子诊断或预后工具,而且作为疾病治疗的潜在靶点也值得进一步研究。